Revitalizing oral cancer research: Crispr-Cas9 technology the promise of genetic editing

被引:1
作者
Sowmya, S. V. [1 ]
Augustine, Dominic [1 ]
Mushtaq, Shazia [2 ]
Baeshen, Hosam Ali [3 ]
Ashi, Heba [4 ]
Hassan, Reem Nabil [5 ]
Alshahrani, Mohammed [6 ]
Patil, Shankargouda [7 ]
机构
[1] MS Ramaiah Univ Appl Sci, Fac Dent Sci, Dept Oral Pathol & Microbiol, Bengaluru, Karnataka, India
[2] King Saud Univ, Coll Appl Med Sci, Dent Hlth Dept, Riyadh, Saudi Arabia
[3] King Abdulaziz Univ, Fac Dent, Dept Orthodont, Jeddah, Saudi Arabia
[4] King Abdulaziz Univ, Fac Dent, Dept Dent Publ Hlth, Jeddah, Saudi Arabia
[5] King Abdulaziz Univ, Fac Sci, Biol Sci Dept Genome, Jeddah, Saudi Arabia
[6] King Abdulaziz Univ, Fac Dent, Endodont Dept, Jeddah, Saudi Arabia
[7] Roseman Univ Hlth Sci, Coll Dent Med, South Jordan, UT USA
关键词
CRISPR-Cas9; gene editing; oral cancer; CRISPR-screens; genetic editing; POOLED IN-VITRO; CLINICAL-TRIAL; 1ST TRIAL; CRISPR/CAS9; CELLS; EFFICIENT; DELIVERY; PROGRESS; THERAPY; SYSTEM;
D O I
10.3389/fonc.2024.1383062
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
This review presents an in-depth analysis of the immense potential of CRISPR-Cas9 technology in revolutionizing oral cancer research. It underscores the inherent limitations of conventional treatments while emphasizing the pressing need for groundbreaking approaches. The unparalleled capability of CRISPR-Cas9 to precisely target and modify specific genes involved in cancer progression heralds a new era in therapeutic intervention. Employing genome-wide CRISPR screens, vulnerabilities in oral cancer cells can be identified, thereby unravelling promising targets for therapeutic interventions. In the realm of oral cancer, the disruptive power of CRISPR-Cas9 manifests through its capacity to perturb genes that are intricately associated with drug resistance, consequently augmenting the efficacy of chemotherapy. To address the challenges that arise, this review diligently examines pertinent issues such as off-target effects, efficient delivery mechanisms, and the ethical considerations surrounding germline editing. Through precise gene editing, facilitated by CRISPR/Cas9, it becomes possible to overcome drug resistance by rectifying mutations, thereby enhancing the efficacy of personalized treatment strategies. This review delves into the prospects of CRISPR-Cas9, illuminating its potential applications in the domains of medicine, agriculture, and biotechnology. It is paramount to emphasize the necessity of ongoing research endeavors and the imperative to develop targeted therapies tailored specifically for oral cancer. By embracing this comprehensive overview, we can pave the way for ground-breaking treatments that instill renewed hope for enhanced outcomes in individuals afflicted by oral cancer.
引用
收藏
页数:13
相关论文
共 102 条
[31]   Combining CRISPR/Cas9 mutagenesis and a small-molecule inhibitor to probe the function of MELK in cancer [J].
Giuliano, Christopher J. ;
Lin, Ann ;
Smith, Joan C. ;
Palladino, Ann C. ;
Sheltzer, Jason M. .
CANCER RESEARCH, 2018, 78 (13)
[32]   Comparison of the Feasibility, Efficiency, and Safety of Genome Editing Technologies [J].
Gonzalez Castro, Nicolas ;
Bjelic, Jan ;
Malhotra, Gunya ;
Huang, Cong ;
Alsaffar, Salman Hasan .
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2021, 22 (19)
[33]   CRISPR-Cas9 genome editing induces a p53-mediated DNA damage response [J].
Haapaniemi, Emma ;
Botla, Sandeep ;
Persson, Jenna ;
Schmierer, Bernhard ;
Taipale, Jussi .
NATURE MEDICINE, 2018, 24 (07) :927-+
[34]  
Haghighi N., 2021, Avicenna J Clin Med, V28, P49, DOI [10.52547/ajcm.28.1.49, DOI 10.52547/AJCM.28.1.49]
[35]   In Vivo Ovarian Cancer Gene Therapy Using CRISPR-Cas9 [J].
He, Zhi-Yao ;
Zhang, Ya-Guang ;
Yang, Yu-Han ;
Ma, Cui-Cui ;
Wang, Ping ;
Du, Wei ;
Li, Ling ;
Xiang, Rong ;
Song, Xiang-Rong ;
Zhao, Xia ;
Yao, Shao-Hua ;
Wei, Yu-Quan .
HUMAN GENE THERAPY, 2018, 29 (02) :223-233
[36]   Randomized dose-finding clinical trial of oncolytic immunotherapeutic vaccinia JX-594 in liver cancer [J].
Heo, Jeong ;
Reid, Tony ;
Ruo, Leyo ;
Breitbach, Caroline J. ;
Rose, Steven ;
Bloomston, Mark ;
Cho, Mong ;
Lim, Ho Yeong ;
Chung, Hyun Cheol ;
Kim, Chang Won ;
Burke, James ;
Lencioni, Riccardo ;
Hickman, Theresa ;
Moon, Anne ;
Lee, Yeon Sook ;
Kim, Mi Kyeong ;
Daneshmand, Manijeh ;
Dubois, Kara ;
Longpre, Lara ;
Ngo, Minhtran ;
Rooney, Cliona ;
Bell, John C. ;
Rhee, Byung-Geon ;
Patt, Richard ;
Hwang, Tae-Ho ;
Kirn, David H. .
NATURE MEDICINE, 2013, 19 (03) :329-336
[37]   High-content CRISPR screening in tumor immunology [J].
Holcomb, Erin A. A. ;
Pearson, Ashley N. N. ;
Jungles, Kassidy M. M. ;
Tate, Akshay ;
James, Jadyn ;
Jiang, Long ;
Huber, Amanda K. K. ;
Green, Michael D. D. .
FRONTIERS IN IMMUNOLOGY, 2022, 13
[38]   Generation and characterization of a human oral squamous carcinoma cell line SCC-9 with CRISPR/Cas9-mediated deletion of the p75 neurotrophin receptor [J].
Huang, Ping ;
Tong, Dongdong ;
Sun, Jing ;
Li, Qing ;
Zhang, Fenghe .
ARCHIVES OF ORAL BIOLOGY, 2017, 82 :223-232
[39]   Applications of CRISPR/Cas9 Technology in the Treatment of Lung Cancer [J].
Jiang, Chunyang ;
Lin, Xiaohui ;
Zhao, Zhigang .
TRENDS IN MOLECULAR MEDICINE, 2019, 25 (11) :1039-1049
[40]   Systemic Delivery of CRISPR/Cas9 Targeting HPV Oncogenes Is Effective at Eliminating Established Tumors [J].
Jubair, Luqman ;
Fallaha, Sora ;
McMillan, Nigel A. J. .
MOLECULAR THERAPY, 2019, 27 (12) :2091-2099